# US 2021/0079015 A1 · Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079015 A1
- Document ID: US20210079015A1
- Status: Published application
- Kind: A1
- Application number: 16/764,525
- Filed: 2018-11-16
- Published: 2021-03-18
- Earliest claimed: 2017-11-17
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Jiping FU; Mika LINDVALL; James R. MANNING; Glenn MCENROE
- Web page: https://patentgrep.com/patent/US20210079015A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61P 31/14: for RNA viruses
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compounds of Formula (I) n R3b Z W Q R3a H Y N R1 R4 R2 O (I) as described herein, along with stereoisomeric forms salts, hydrates, solvates, and salts thereof and pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

## Claims

### Claim 1

A compound of formula (I):
a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein:
R1 is aryl or heteroaryl containing one or more heteroatoms each independently selected from N, O and S as a ring member, said aryl or heteroaryl being unsubstituted or substituted with one or more substituents independently selected from C1-8alkyl, C3-8-cycloalkyl, cyano, C1-8alkoxy, haloC1-8alkyl, and halogen;
Y is CH, C— C1-8alkyl, or N;
W is C or CH if Y is N, and W is O when Y is CI or C—C1-8alkyl;
Q is O, N or NH;
Z is O if Q is N or NH; and Z is N or NH, if Q is O;
n indicates an integer of 1 or 2;
each R2, R3a and R3b are independently H or C1-C8 alkyl or R3a and R3b can be taken together to form a C3-8cycloalkyl;
R4 is a 3-9 membered saturated monocyclic, bridged, unbridged or spiro bicyclic ring that can optionally contain one or more heteroatoms each independently selected from N, O and S as a ring member, and can be unsubstituted or substituted by one or more groups independently selected from —C1-C8alkyl, hydroxyC1-C8alkyl, —NR52, —CN, —COR5, —COOR5, —CONR52, —OH, oxo, halo, —SOR5, −SO2OR5, —SO2NR52, —(C1-C8alkylene)m-R5, —(C1-C8alkylene)m-R6, —(C1-C8alkylene)m-O—R6, —(C1-C8alkylene)m-SO2—R6 and —O—(C1-C8alkylene)m-R6;
each R5 is independently selected from C1-C8alkyl, —COC1-C8alkyl, —COR6, hydroxyC1-C8alkyl, C1-C8alkoxy, haloC1-C8alkyl, —SO2C1-C8alkyl, aryl and heteroaryl; each of said aryl or heteroaryl which can be unsubstituted or substituted by one or more groups independently selected from C1-C8alkyl, —OH, C1-C8alkoxy and halo;
each R6 is independently heteroaryl or a 3-9 membered saturated monocyclic, bridged, unbridged or spiro bicyclic ring that can optionally contain one or more heteroatoms each independently selected from N, O and S as a ring member, and can be substituted by one or more groups independently selected from C1-C8alkyl, CN, —OH, C1-C8alkoxy and halo;
m is 0 or 1;
or R4 is phenyl, said phenyl being unsubstituted or substituted with one or more substituents independently selected from halogen, cyano, hydroxy, C1-6alkyl, C1-6alkoxy, C3-8cycloalkyl, haloC1-6alkoxy and halo C1-6alkyl; C3-8-cycloalkyl, −SO2OR5, and —SO2NR52;
or R4 is heteroaryl, said heteroaryl being unsubstituted or substituted with one or more substituents independently selected from halogen, cyano, hydroxy, C1-6alkyl, C1-6alkoxy, C3-8cycloalkyl, haloC1-6alkoxy and halo C1-6alkyl; or C3-8-cycloalkyl; and
represents a single or double bond.

### Claim 2 (depends on 1)

A compound of claim 1 having the formula (II):
a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein:
each R7, R8, and R9 are independently H, halo, C1-C8 alkyl, CN, and C1-C8haloalkyl; and
V is C, CH or N.

### Claim 3 (depends on 1)

A compound of claim 1 having the formula (III):
a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein:
each R7, R8, and R9 are independently H, halo, C1-C8 alkyl, CN, and C1-C8haloalkyl; and
V is C, CH or N.

### Claim 4 (depends on 2)

A compound of claim 2 having the formula (IV):
a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein:
R10 and R11 are independently H, halo, C1-C8 alkyl, CN, and C1-C8haloalkyl.

### Claim 5 (depends on 2)

A compound of claim 2 having the formula (V):
a stereoisomer thereof or a pharmaceutically acceptable salt thereof; wherein:
U is CR152, NR16 or O;
R12 is H, C1-C8alkyl, hydroxyC1-C8alkyl, —NR52, —CN, —COR5, −COOR5, —CONR52, —OH, C1-C8haloalkoxy, —SOR5, —SO2NR52, —(C1-C8alkylene)m-R6, —(C1-C8alkylene)m-O—R6 and —O—(C1-C8alkylene)m-R6, —(C1-C8alkylene)m-SO2—R6, heteroaryl or heteroaryloxy, wherein each of heteroaryl or heteroaryloxy are unsubstituted or optionally substituted with C1-C8alkyl, or is taken together with R13 to form a C3-C8cycloalkyl ring;
R13 is H, C1-C8 alkyl, or taken together with R12 to form a C3-C8cycloalkyl ring;
R14 is H or is taken together with R15 to form a C3-C8cycloalkyl ring;
each R15 independently selected from H, or C1-C8alkyl, hydroxyC1-C8alkyl, —NR52, —OH, —(C1-C8alkylene)m-R5, —(C1-C8alkylene)m-R6, —(C1-C8alkylene)m-O—R6 and —O—(C1-C8alkylene)m-R6, —(C1-C8alkylene)m-SO2—R6 or one R15 may be taken together with R14 to form a C3-C8cycloalkyl ring; and
R16 is selected from H, C1-C8alkyl, hydroxyC1-C8alkyl, —COR5, −COOR5, —CONR52, —S2OR5, —SO2NR52, —(C1-C8alkylene)m-R6, —(C1-C8alkylene)m-θ-R6 and —(C1-C8alkylene)m-SO2—R6.

### Claim at position 6

-17. (canceled)

### Claim 18 (depends on 1)

The compound of claim 1, which is selected from the compound 3-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; 3-cyclohexyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; 3-(2,4-difluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(2,4-difluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (R)-3-(2,4-difluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; 3-(2,4-difluorophenyl)-4-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; 3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; 3-(2-oxooxazolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; 3-(pyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; 3-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydrobenzo[c]isoxazole-5-carboxamide; 3-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,5-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(4-methoxyphenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(2-fluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(p-tolyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(2-chlorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(4-fluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(3-cyanophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-phenyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(4-(trifluoromethoxy)phenyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(o-tolyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(4-chlorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(4-cyanophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(3-methoxyphenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(3-fluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(3-chlorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(m-tolyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(4-(difluoromethoxy)phenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(5-methylisoxazol-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-4-methyl-3-(5-methylisoxazol-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(5-fluoropyridin-2-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(5-fluoropyridin-2-yl)-4-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(2-methylthiazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-4-methyl-3-(2-methylthiazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(1-methyl-1H-pyrazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-4-methyl-3-(1-methyl-1H-pyrazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(1-methyl-1H-pyrazol-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-4-methyl-3-(1-methyl-1H-pyrazol-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(2-methyloxazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-4-methyl-3-(2-methyloxazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-4-methyl-3-(1-methyl-1H-1,2,3-triazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(2,5-dimethyloxazol-4-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(2,5-dimethyloxazol-4-yl)-4-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(5-methyl-1,2,4-oxadiazol-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-4-methyl-3-(5-methyl-1,2,4-oxadiazol-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-cyclopentyl-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-cyclopentyl-4-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; N-(3-(difluoromethyl)-4,5-difluorophenyl)-3-(2-oxo-1,3-oxazinan-3-yl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(2-oxopiperidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)—N-(4-cyano-3-fluorophenyl)-6-methyl-3-(2-oxopiperidin-1-yl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(2-oxo-1,3-oxazinan-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(3-oxomorpholino)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)—N-(3-(difluoromethyl)-4-fluorophenyl)-6-methyl-3-(2-oxo-1,3-oxazinan-3-yl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)—N-(3-(difluoromethyl)-4,5-difluorophenyl)-6-methyl-3-(2-oxo-1,3-oxazinan-3-yl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)—N-(2-(difluoromethyl)pyridin-4-yl)-6-methyl-3-(2-oxo-1,3-oxazinan-3-yl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)—N-(3-cyano-4-fluorophenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(2-oxopiperidin-1-yl)-N-phenyl-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-(2-oxooxazolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (6S)-6-methyl-3-(3-methyl-2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(3,3-dimethyl-2-oxopyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(1,1-dioxidoisothiazolidin-2-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-6-methyl-3-morpholino-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-(2,5-dioxopyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-((S)-5-(methoxymethyl)-2-oxooxazolidin-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; (S)-3-((R)-5-(methoxymethyl)-2-oxooxazolidin-3-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydroisoxazolo[4,3-c]pyridine-5(4H)-carboxamide; and 2-(1-((S)-6-methyl-5-((3,4,5-trifluorophenyl)carbamoyl)-4,5,6,7-tetrahydroisoxazolo[4,3-c]pyridin-3-yl)-2-oxopyrrolidin-3-yl)acetic acid.

### Claim 19 (depends on 1)

A pharmaceutical composition, comprising a compound of claim 1 admixed with at least one pharmaceutically acceptable carrier.

### Claim 20 (depends on 1, 19)

A method to treat a subject having a hepatitis B infection, which comprises administering to the subject a compound of claim 1 or a pharmaceutical composition of claim 19.

### Claim 21 (depends on 1, 19, 20)

The method of claim 20, wherein the compound of claim 1 or the pharmaceutical composition of claim 19 is used in combination with an additional therapeutic agent selected from an interferon or peginterferon, an HBV polymerase inhibitor, a viral entry inhibitor, a viral maturation inhibitor, a capsid assembly inhibitor, an HBV core modulator, a reverse transcriptase inhibitor, a TLR-agonist, or an immunomodulator.

### Claim 22 (depends on 1)

A method to inhibit replication of hepatitis B virus, which comprises contacting the hepatitis B virus, either in vitro or in vivo, with a compound according to claim 1.

### Claim 23 (depends on 1)

A pharmaceutical combination, comprising a compound of claim 1 and at least one additional therapeutic agent.

### Claim 24 (depends on 1)

A compound according to claim 1 for use in therapy.

### Claim 25 (depends on 24)

The compound according to claim 24 wherein the therapy is treatment of a viral infection.

### Claim 26 (depends on 1)

Use of a compound according to claim 1 in the manufacture of a medicament.
